The use of bisphosphonates in the treatment of osteoporosis

Current Opinion in Rheumatology

Volumn 17, Issue 4, 2005, Pages 462-466

  Delmas, Pierre D ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Bisphosphonates; Bone turnover; Fragility fractures; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; IBANDRONIC ACID; NERIDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ANDROGEN DEFICIENCY; BONE DENSITY; BONE EROSION; BONE INJURY; BONE NECROSIS; BONE TURNOVER; CANCER THERAPY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG WITHDRAWAL; FRACTURE NONUNION; HUMAN; LONG TERM CARE; NONHUMAN; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RHEUMATOID ARTHRITIS; SECONDARY OSTEOPOROSIS; TREATMENT PLANNING; VERTEBRA FRACTURE;

ALENDRONATE; BONE DENSITY; ETIDRONIC ACID; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; MALE; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 23044489173     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000163448.51661.87     Document Type: Review

References (36)

1. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002; 359:2018-2026.
2. Boonen S, McClung MR, Eastell R, et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004; 52:1832-1839.
3. Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004; 20:433-439.
4. Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 74:129-135.
5. Harris ST, Watts NB, Li Z, et al. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 2004; 20:757-764.
6. Johnell O, Jonsson B, Jonsson L, Black D. Cost effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003; 21:305-314.
7. Borgstrom F, Johnell O, Jonsson B, et al. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 2004; 34:1064-1071. Important health economy study showing that it is cost effective to treat men with severe osteoporosis.
8. Kanis JA, Borgstrom F, Johnell O, Jonsson B. Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 2004; 15:862-871. Important health economy study demonstrating that it is cost effective to treat postmenopausal women with osteoporosis, even those without fractures.
9. Sambrook PN, Rodriguez JP, Wasnich RD, et al. Alendronate in the prevention of osteoporosis: 7-year follow-up. Osteoporos Int 2004; 15:483-488.
10. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333:1437-1443.
11. Devogelaer JP, Broll H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996; 18:141-150.
12. Tucci JR, Tonino RP, Emkey RD, et al. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996; 101:488-501.
13. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350:1189-1199. The first long-term prospective study showing the effects of a bisphosphonate on BMD and bone turnover.
14. Bjarnason NH. Ten years of alendronate treatment for osteoporosis in post-menopausal women. N Engl J Med 2004; 351:190-192; author reply 190-192.
15. Ott SM. Ten years of alendronate treatment for osteoporosis in postmenopausal women. N Engl J Med 2004; 351:190-192; author reply 190-192.
16. Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004; 19:1259-1269. Long-term study of women with osteoporosis treated with alendronate.
17. Black D, Schwarz A, Ensrud K, et al. A 5 year randomized trial of the long-term efficacy and safety of alendronate: the FIT Long-Term Extension (FLEX). J Bone Miner Res 2004; 19(Suppl 1):S45.
18. Mellstrom DD, Sorensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75:462-468.
19. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352:154-164.
20. Delmas PD, Chapuy MC, Edouard C, Meunier PJ. Beneficial effects of amin-ohexane diphosphonate in patients with Paget's disease of bone resistant to sodium etidronate. Am J Med 1987; 83:276-282.
21. Morabito N, Gaudio A, Lasco A, et al. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer. J Bone Miner Res 2004; 19:1766-1770.
22. Shane E, Addesso V, Namerow PB, et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 2004; 350:767-776.
23. Herrak P, Gortz B, Hayer S, et al. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum 2004; 50:2327-2337.
24. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19:1241-1249.
25. Delmas PD, Recker RR, Chesnut CH 3rd, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004; 15:792-798.
26. Recker R, Stakkestad JA, Chesnut CH 3rd, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004; 34:890-899.
27. Adami S, Felsenberg D, Christiansen C, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 2004; 34:881-889.
28. Delmas PD, Li Z, Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res 2004; 19:330-337. A comprehensive analysis of the interpretation of studies examining the relationship between change in BMD and fracture risk in patients with osteoporosis treated with antiresorptive drugs.
29. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18:1051-1056.
30. Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the Fracture Intervention Trial. J Bone Miner Res 2004; 19:1250-1258. This study shows that the early decrease in markers is associated with the risk of vertebral and nonvertebral fractures in patients treated with alendronate.
31. Nakatsuka K, Miki T, Naka H, et al. Long-term effect of intermittent cyclical etidronate on microarchitecture and quality of trabecular bone in an elderly woman with severe osteoporosis. J Bone Miner Metab 2004; 22:153-158.
32. Day JS, Ding M, Bednarz P, et al. Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties. J Orthop Res 2004; 22:465-471.
33. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62:527-534.
34. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; (90:1294-1301.) [Epub ahead of print].
35. Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004; 19:745-751.
36. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349:1207-1215.